Video

Dr. Meeks on the Importance of p53 and Rb1 in Bladder Cancer

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.

P53 is not a biomarker, although it is present in over 70% of muscle-invasive tumors, says Meeks. The same frequency is found in patients with T1 tumors. P53 plays an integral role in bladder cancer. As was reflected in genetic models in mice, it was discovered that a patient is going to lose p53 and Rb1 expression in almost all of these tumors.

As the field progresses, subtypes will become more prominent, explains Meeks. Currently, the 5 subtypes are luminal papillary, true luminal, luminal-infiltrated, basal, and neuronal. As physicians uncover more about these tumors, subtyping will become more important to the prognostication and prediction of certain therapies—both chemotherapy and immunotherapy, he concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity